S. B. Edge and C. C. Compton, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, vol.17, issue.6, pp.1471-1475, 2010.

A. V. D'amico, R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, vol.280, issue.11, p.9749478, 1998.

M. De-rooij, E. Hamoen, J. A. Witjes, J. O. Barentsz, and M. M. Rovers, Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis, Eur Urol, vol.70, issue.2, p.26215604, 2016.

A. Morlacco, V. Sharma, B. R. Viers, L. J. Rangel, R. E. Carlson et al., The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy, Eur Urol, vol.71, issue.5, p.27576750, 2017.

N. Grivas, K. Hinnen, J. De-jong, W. Heemsbergen, L. Moonen et al., Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology, Eur J Radiol, vol.98, p.29279147, 2018.

F. Cornud, T. Flam, L. Chauveinc, K. Hamida, Y. Chré-tien et al., Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results, Radiology, vol.224, issue.1, p.12091684, 2002.

J. S. Brajtbord, H. J. Lavery, F. Nabizada-pace, P. Senaratne, and D. B. Samadi, Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer, BJU Int, vol.107, issue.9, p.20804475, 2011.

M. Hubanks, J. Boorjian, S. A. Frank, I. Gettman, M. T. et al., The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes, Urol Oncol, vol.32, issue.1, pp.26-27, 2014.

W. S. Jang, C. Y. Yoon, K. H. Kim, Y. J. Kang, S. Shin et al., Prognostic Significance of Vas Deferens Invasion After Radical Prostatectomy in Patients with Pathological Stage T3b Prostate Cancer, Ann Surg Oncol, vol.24, issue.4, p.27796593, 2017.

C. Bastide, D. Rossi, E. Lechevallier, F. Bladou, D. Barriol et al., Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int, vol.109, p.21851534, 2012.

H. J. Lee, J. Han, D. H. Lee, J. K. Nam, T. N. Kim et al., Does bilateral seminal vesicle invasion at radical prostatectomy predict worse prognosis than unilateral invasion among patients with pT3b prostate cancers?, Int J Urol Off J Jpn Urol Assoc, vol.23, issue.9, pp.758-63, 2016.

A. Kristiansen, L. Drevin, B. Delahunt, H. Samaratunga, D. Robinson et al., Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology (Phila), vol.49, pp.715-735, 2017.

G. E. Hanks, T. F. Pajak, A. Porter, D. Grignon, H. Brereton et al., Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, issue.21, pp.3972-3980, 2003.

M. Bolla, T. M. De-reijke, G. Van-tienhoven, A. Van-den-bergh, J. Oddens et al., Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, vol.360, issue.24, p.19516032, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00492521

C. Salembier, G. Villeirs, D. Bari, B. Hoskin, P. Pieters et al., ESTRO ACROP consensus guideline on CT-and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.127, issue.1, pp.49-61, 2018.

J. K. Ryu, K. Winter, J. M. Michalski, J. A. Purdy, A. M. Markoe et al., Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy), Int J Radiat Oncol Biol Phys, vol.54, issue.4, p.12419429, 2002.

L. B. Marks, E. D. Yorke, A. Jackson, R. K. Ten-haken, L. S. Constine et al., Use of normal tissue complication probability models in the clinic, Int J Radiat Oncol Biol Phys, vol.76, issue.3, p.20171502, 2010.

V. Beckendorf, S. Guerif, L. Prisé, E. Cosset, J. Bougnoux et al., 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial, Int J Radiat Oncol Biol Phys, vol.80, issue.4, p.21147514, 2011.

J. M. Michalski, J. Moughan, J. Purdy, W. Bosch, D. W. Bruner et al., Effect of Standard vs DoseEscalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial, JAMA Oncol, 2018.

C. Fiorino, R. Valdagni, T. Rancati, and G. Sanguineti, Dose-volume effects for normal tissues in external radiotherapy: pelvis, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.93, issue.2, pp.153-67, 2009.

D. E. Spratt, X. Pei, J. Yamada, M. A. Kollmeier, B. Cox et al., Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, vol.85, issue.3, p.22795805, 2013.

O. Cahlon, M. Hunt, and M. J. Zelefsky, Intensity-modulated radiation therapy: supportive data for prostate cancer, Semin Radiat Oncol, vol.18, issue.1, p.18082588, 2008.

F. N. Soylu, Y. Peng, Y. Jiang, S. Wang, C. Schmid-tannwald et al., Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging, Radiology, vol.267, issue.3, p.23440325, 2013.

C. J. Mcmahon, N. M. Rofsky, and I. Pedrosa, Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging, Radiology, vol.254, issue.1, pp.31-46, 2010.

M. Roach, G. Hanks, H. Thames, P. Schellhammer, W. U. Shipley et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, vol.65, issue.4, p.16798415, 2006.

J. M. Michalski, K. Winter, J. A. Purdy, M. Parliament, H. Wong et al., Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V, Int J Radiat Oncol Biol Phys, vol.62, issue.3, p.15936549, 2005.

M. J. Zelefsky, E. J. Levin, M. Hunt, Y. Yamada, A. M. Shippy et al., Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, vol.70, issue.4, p.18313526, 2008.

S. Peeters, W. D. Heemsbergen, P. Koper, W. Van-putten, A. Slot et al., Doseresponse in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, issue.13, pp.1990-1996, 2006.

A. Pollack, G. K. Zagars, G. Starkschall, J. A. Antolak, J. J. Lee et al., Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial, Int J Radiat Oncol Biol Phys, vol.53, issue.5, p.12128107, 2002.

O. Cahlon, M. J. Zelefsky, A. Shippy, H. Chan, Z. Fuks et al., Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes, Int J Radiat Oncol Biol Phys, vol.71, issue.2, p.18164858, 2008.

Y. Sheng, T. Li, W. R. Lee, F. Yin, and Q. J. Wu, Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis, Int J Radiat Oncol Biol Phys, vol.98, issue.2, p.28463167, 201701.

M. Van-der-burgt, L. Bergsma, J. De-vries, F. J. Pos, R. Kalisvaart et al., Impact of tumour invasion on seminal vesicles mobility in radiotherapy of prostate cancer, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.117, issue.2, pp.283-290, 2015.

J. Liang, Q. Wu, and D. Yan, The role of seminal vesicle motion in target margin assessment for online imageguided radiotherapy for prostate cancer, Int J Radiat Oncol Biol Phys, vol.73, issue.3, p.19111401, 2009.

M. Moschini, V. Sharma, G. Gandaglia, P. Dell'oglio, N. Fossati et al., Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy, BJU Int, vol.120, issue.1, p.27753192, 2017.

M. J. Pagano, M. J. Whalen, D. J. Paulucci, B. N. Reddy, J. T. Matulay et al., Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy. The Prostate, vol.76, p.26481325, 2016.

G. P. Swanson, B. Goldman, C. M. Tangen, J. Chin, E. Messing et al., The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794, J Urol, vol.180, issue.6, p.18930488, 2008.

L. Salomon, A. G. Anastasiadis, C. W. Johnson, J. M. Mckiernan, E. T. Goluboff et al., Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression, Urology, vol.62, issue.2, p.12893340, 2003.

S. J. Freedland, W. J. Aronson, J. C. Presti, C. L. Amling, M. K. Terris et al., Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer, vol.100, p.15073850, 2004.

I. S. Dayes, S. Parpia, J. Gilbert, J. A. Julian, I. R. Davis et al., Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate, Int J Radiat Oncol Biol Phys, vol.99, issue.1, p.28816169, 201701.

S. Rodda, S. Tyldesley, W. J. Morris, M. Keyes, R. Halperin et al., ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High-and Intermediate-Risk Prostate Cancer

, Int J Radiat Oncol Biol Phys, vol.98, issue.2, p.28433432, 201701.

P. J. Hoskin, A. M. Rojas, P. J. Bownes, G. J. Lowe, P. J. Ostler et al., Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.103, issue.2, pp.217-239, 2012.

A. Amini, B. Jones, M. W. Jackson, N. Yeh, T. V. Waxweiler et al., Survival Outcomes of DoseEscalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base, J Urol, vol.195, issue.5, p.26576709, 2016.

R. D. Ennis, L. Hu, S. N. Ryemon, J. Lin, and M. Mazumdar, Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.12, pp.1192-1200, 2018.

N. N. Stone, V. M. Skouteris, and R. G. Stock, Biopsy and implantation of the seminal vesicles, Brachytherapy, vol.11, issue.5, p.22305509, 2012.

D. Rades, R. Schwarz, M. Todorovic, H. Thurmann, M. Graefen et al., Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer, Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al, vol.183, issue.7, pp.398-402, 2007.

H. Tsumura, H. Ishiyama, K. Tabata, H. Katsumata, M. Kobayashi et al., Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing highdose-rate brachytherapy. The Prostate, vol.77, p.28905446, 2017.

N. N. Stone and R. G. Stock, Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy, BJU Int, 2018.

P. G. Koutrouvelis, J. Gillenwater, N. Lailas, F. Hendricks, S. Katz et al., High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.67, issue.3, pp.303-311, 2003.

A. Van-hemelryk, D. Meerleer, G. Ost, P. Poelaert, F. et al., The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients, Int J Radiat Oncol Biol Phys, vol.96, issue.2, p.27598803, 201601.

J. R. Broughman and R. C. Chen, Management of Node-Positive and Oligometastatic Prostate Cancer, Semin Radiat Oncol, vol.27, issue.1, p.27986214, 2017.

C. C. Lin, P. J. Gray, A. Jemal, and J. A. Efstathiou, Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer, J Natl Cancer Inst, vol.107, issue.7, 2015.

C. G. Rusthoven, J. A. Carlson, T. V. Waxweiler, D. Raben, P. E. Dewitt et al., The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study, Int J Radiat Oncol Biol Phys, vol.88, issue.5, p.24661660, 2014.

T. Seisen, M. W. Vetterlein, P. Karabon, T. Jindal, A. Sood et al., Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis, Eur Urol, 2017.

K. A. Touijer, R. J. Karnes, N. Passoni, D. D. Sjoberg, M. Assel et al., Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies, Eur Urol, vol.73, issue.6, p.29042125, 2018.

F. Abdollah, D. Dalela, A. Sood, J. Keeley, S. Alanee et al., Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection, Eur Urol, vol.74, issue.3, p.29720348, 2018.

M. Sofer, M. Savoie, S. S. Kim, F. Civantos, and M. S. Soloway, Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion, J Urol, vol.169, issue.1, p.12478125, 2003.